Almost 2 Years Ago
1 Min Read
Off goes PLRX. The stock lost today. Here's why:
PLIANT THERAPEUTICS, INC. (PLRX) is trading -7% lower at $18.665 today. The drop in price comes amid news the company is going to offer a large $200M stock offering. That being said, the stock remains well above it's 52-week low.
PLIANT THERAPEUTICS, INC. has been trading between a 52-week high of $27.01 and a 52-week low of $3.97. The stock has a market cap of $675 Million.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC.
PLIANT THERAPEUTICS, INC. has been trading between a 52-week high of $27.01 and a 52-week low of $3.97. The stock has a market cap of $675 Million.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC.
Recommended Articles
